Active Biotech

Active Biotech’s election committee appointed

November 19, 2019

Active Biotech Interim report January – September 2019

November 14, 2019

New preclinical data on naptumomab estafenatox will be presented at the Society for Immunotherapy of Cancer’s 34th Annual Meeting

November 5, 2019

Active Biotech and NeoTX today announce first patient dosed in the Phase 1b trial of naptumomab estafenatox in combination with durvalumab in solid tumors

October 28, 2019

New data on laquinimod from the Phase 2 LEGATO-HD study in Huntington’s disease will be presented at the International congress of Parkinson’s disease and movement disorders

September 23, 2019

Active Biotech AB: Interim report January – June 2019

August 8, 2019

The Annual General Meeting of Active Biotech was held on May 23, 2019

May 24, 2019

The Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at the scientific conference “American Academy of Neurology – AAN” in Philadelphia, PA, on May 6 2019

May 3, 2019

The Election Committee of Active Biotech AB proposes Michael Shalmi to be appointed new Chairman of the Board and Uli Hacksell to be appointed new member of the Board

May 2, 2019

Annual Report 2018 Active Biotech AB (publ)

April 26, 2019

Active Biotech AB – Interim report January – March 2019

April 25, 2019

Active Biotech: NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

April 24, 2019

Active Biotech completes sale of property

April 5, 2019

An Extraordinary General Meeting of Active Biotech AB was held on April 4, 2019

April 5, 2019

Active Biotech has entered into an agreement regarding sale of the Company’s property – extraordinary general meeting on April 4, 2019

March 13, 2019

Active Biotech Year-end report January – December 2018

February 14, 2019

Active Biotech’s partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study

February 11, 2019

Active Biotech has received an indicative bid for the property in Lund – the Board is positive

February 1, 2019

Active Biotech provides updated information about the company’s financial position

December 10, 2018

Interim report January – September 2018

November 15, 2018

New data from the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at the scientific conference HSG 2018

November 8, 2018

<\span>

Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at “European Huntington’s Disease Network (EHDN) plenary meeting 2018”

September 13, 2018

Active Biotech regains global rights to development and commercialization of laquinimod

September 5, 2018

Active Biotech AB – Interim Report January – June 2018

August 9, 2018

Active Biotech provides update on laquinimod in Huntington’s disease

July 31, 2018

The Annual General Meeting of Active Biotech was held on May 17, 2018

May 17, 2018

Annual Report 2017 Active Biotech AB (publ)

April 27, 2018

Notice of Annual General Meeting of Shareholders May 17, 2018, at 5 pm

April 18, 2018

Active Biotech’s rights issue over subscribed

April 16, 2018

Active Biotech’s partner NeoTX presents new data at AACR demonstrating that ANYARA enhances the efficacy of checkpoint blockade in preclinical models of cancer

April 12, 2018

Prospectus relating to Active Biotech’s rights issue published

March 27, 2018

Extraordinary General Meeting of Active Biotech AB

March 19, 2018

Active Biotech carries out rights issue

February 15, 2018

Active Biotech AB Year-end report January – December 2017